- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/40 - Oxygen atoms
Patent holdings for IPC class C07D 211/40
Total number of patents in this class: 115
10-year publication summary
10
|
5
|
8
|
8
|
7
|
5
|
6
|
8
|
10
|
3
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
FMC Corporation | 847 |
5 |
Theravance Biopharma R&D IP, LLC | 460 |
5 |
ChemoCentryx, Inc. | 387 |
4 |
F. Hoffmann-La Roche AG | 7934 |
3 |
AstraZeneca AB | 2928 |
3 |
Amgen Inc. | 4071 |
3 |
Bristol-myers Squibb Company | 4879 |
2 |
Board of Regents, The University of Texas System | 5763 |
2 |
ABAC Therapeutics S.L. | 7 |
2 |
Athenex, Inc. | 26 |
2 |
Neurocrine Biosciences, Inc. | 409 |
2 |
Nippon Soda Co., Ltd. | 894 |
2 |
Sirna Therapeutics, Inc. | 111 |
2 |
Idorsia Pharmaceuticals Ltd. | 350 |
2 |
Shanghai Meizer Pharmaceuticals Co., Ltd. | 14 |
2 |
Vividion Therapeutics, Inc. | 34 |
2 |
ReNAgade Therapeutics Management Inc. | 44 |
2 |
Hong Kong King-friend Industrial Company Ltd. | 40 |
2 |
Hoffmann-La Roche Inc. | 3404 |
1 |
BASF SE | 20892 |
1 |
Other owners | 66 |